GlassScriptPhysician profile
Katherine Perez
NPI 1073060851
$4,102.94
in general payments reported to CMS, 2019-2025
14 companies · $3,102 in 2025
The $3,102 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $81.66 · 2023: $288 · 2024: $290 · 2025: $3,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857 · Travel and Lodging: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.12 |
| Travel and Lodging | $1,822.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,051.20 | 2023-2025 | Linq II, Micra |
| Cvrx, INC. | $959.93 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.15 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $169.58 | 2023-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $162.63 | 2024-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $128.93 | 2021 | |
| Amgen INC. | $124.99 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $79.07 | 2023 | Opsumit, Uptravi |
| Bard Peripheral Vascular, INC. | $60.48 | 2021 | |
| Boston Scientific Corporation | $57.02 | 2021-2025 | Opticross 35, General - Angiography |
| Lilly USA, LLC | $24.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.38 | 2022 | |
| Biotronik INC. | $15.47 | 2025 | Biomonitor |
| Novartis Pharmaceuticals Corporation | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.